MX2024008529A - Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. - Google Patents
Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.Info
- Publication number
- MX2024008529A MX2024008529A MX2024008529A MX2024008529A MX2024008529A MX 2024008529 A MX2024008529 A MX 2024008529A MX 2024008529 A MX2024008529 A MX 2024008529A MX 2024008529 A MX2024008529 A MX 2024008529A MX 2024008529 A MX2024008529 A MX 2024008529A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- methods
- eye disease
- thyroid eye
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266549P | 2022-01-07 | 2022-01-07 | |
| PCT/US2023/060207 WO2023133486A2 (en) | 2022-01-07 | 2023-01-06 | Compositions and methods for treatment of thyroid eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008529A true MX2024008529A (es) | 2024-08-26 |
Family
ID=87074299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008529A MX2024008529A (es) | 2022-01-07 | 2023-01-06 | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240343814A1 (https=) |
| EP (1) | EP4460525A4 (https=) |
| JP (1) | JP2025503614A (https=) |
| KR (1) | KR20240141213A (https=) |
| CN (1) | CN118974086A (https=) |
| AU (1) | AU2023205789A1 (https=) |
| CA (1) | CA3242661A1 (https=) |
| MX (1) | MX2024008529A (https=) |
| WO (1) | WO2023133486A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| WO2025014774A1 (en) | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
| WO2025106642A1 (en) * | 2023-11-14 | 2025-05-22 | Tourmaline Bio, Inc. | Methods for the treatment of thyroid eye disease |
| WO2025136985A1 (en) * | 2023-12-17 | 2025-06-26 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120060877A (ko) * | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN113402602B (zh) * | 2020-03-17 | 2022-09-23 | 上海祥耀生物科技有限责任公司 | 一种新型冠状病毒SARS-CoV-2中和性抗体及应用 |
-
2023
- 2023-01-06 MX MX2024008529A patent/MX2024008529A/es unknown
- 2023-01-06 KR KR1020247026160A patent/KR20240141213A/ko active Pending
- 2023-01-06 CA CA3242661A patent/CA3242661A1/en active Pending
- 2023-01-06 EP EP23737769.2A patent/EP4460525A4/en active Pending
- 2023-01-06 AU AU2023205789A patent/AU2023205789A1/en active Pending
- 2023-01-06 WO PCT/US2023/060207 patent/WO2023133486A2/en not_active Ceased
- 2023-01-06 JP JP2024540897A patent/JP2025503614A/ja active Pending
- 2023-01-06 CN CN202380025602.XA patent/CN118974086A/zh active Pending
-
2024
- 2024-07-01 US US18/760,575 patent/US20240343814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240343814A1 (en) | 2024-10-17 |
| KR20240141213A (ko) | 2024-09-25 |
| CA3242661A1 (en) | 2023-07-13 |
| CN118974086A (zh) | 2024-11-15 |
| JP2025503614A (ja) | 2025-02-04 |
| WO2023133486A3 (en) | 2023-08-31 |
| WO2023133486A2 (en) | 2023-07-13 |
| AU2023205789A1 (en) | 2024-07-18 |
| EP4460525A2 (en) | 2024-11-13 |
| EP4460525A4 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008529A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| CR20230204A (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| CO2020015172A2 (es) | Anticuerpos biespecíficos contra dll3-cd3 | |
| CO2021006869A2 (es) | Anticuerpos humanizados contra c-kit | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| MX2024008530A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
| EA201991071A1 (ru) | Композиции и способы для лечения ezh2-опосредованного рака | |
| CL2018001577A1 (es) | Anticuerpos anti-c5 y métodos de uso | |
| MX391279B (es) | Anticuerpos biespecíficos contra cd3 y cd20. | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| MX2018015100A (es) | Composicion y metodo para reducir la neutropenia. | |
| MX2020009379A (es) | Anticuerpos. | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| MX2020006105A (es) | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2022002259A1 (es) | Anticuerpos anti-axl y composiciones | |
| MX2021014103A (es) | Compuestos de briostatina para mejorar la inmunoterapia. | |
| CO2022003053A2 (es) | Proteínas de unión a antígenos | |
| CL2021001312A1 (es) | Anticuerpos agonistas de flt3 y usos de estos | |
| UY39178A (es) | Compuesto de fenilo y método para controlar enfermedades vegetales | |
| CL2023003033A1 (es) | Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica. | |
| MX2023012633A (es) | Metodos de tratamiento de la enfermedad de injerto contra hospedero. | |
| MX2022000332A (es) | Anticuerpos contra el receptor de muerte celular programada pd-1 humano. | |
| ECSP22004680A (es) | Anticuerpos anti-angpt2 |